Stockreport

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 [Yahoo! Finance]

Supernus Pharmaceuticals, Inc.  (SUPN) 
Last supernus pharmaceuticals, inc. earnings: 2/25 04:40 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.supernus.com
PDF SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in-class intracellular modulator of mTORC1 for the treatment of depression ROCKVILLE, M [Read more]